Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients-Reference-Cited by-同舟云学术

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients

Published:2013-11-06 Issue:3 Volume:24 Page:390-398
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Koike Takao,Harigai Masayoshi,Ishiguro Naoki,Inokuma Shigeko,Takei Syuji,Takeuchi Tsutomu,Yamanaka Hisashi,Haruna Shigenori,Ushida Naoko,Kawana Katsuyoshi,Tanaka Yoshiya

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

http://www.tandfonline.com/doi/pdf/10.3109/14397595.2013.843760

Reference41 articles.

1. New therapies for treatment of rheumatoid arthritis

2. The pathogenesis of rheumatoid arthritis: new insights from old clinical data?

3. Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care

4. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real‐world finding;Immunity, Inflammation and Disease;2024-02

2. Factors Influencing Adalimumab Treatment Response in Patients with Rheumatoid Arthritis: The Future of Clinical Expertise;Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 );2023-09-04

3. Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance;Modern Rheumatology;2023-07-03

4. Better Safe than Sorry: Rheumatoid Arthritis, Interstitial Lung Disease, and Medication—A Narrative Review;Biomedicines;2023-06-19

5. Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease modifying antirheumatic drug;Rheumatology;2023-02-14